HHS removes surgeon general's gun violence advisory from its website
The US Department of Health and Human Services has removed the 2024 surgeon general's advisory on gun violence from its website. A link to the Office of the Surgeon General's publications on firearm violence displays a 'Page Not Found' message.
'HHS and the Office of the Surgeon General are complying with President Trump's Executive Order on Protecting Second Amendment Rights,' HHS spokesman Andrew Nixon said in an email Tuesday.
Trump issued an executive order last month calling for the attorney general to 'examine all orders, regulations, guidance, plans, international agreements, and other actions of executive departments and agencies' related to Second Amendment rights and all 'Presidential and agencies' actions from January 2021 through January 2025 that purport to promote safety but may have impinged on the Second Amendment rights of law-abiding citizens.'
In June, Surgeon General Dr. Vivek Murthy declared in a major advisory that gun violence in the United States is a public health crisis and demanded urgent action, calling for more research and stronger laws to reduce harm.
The advisory was the first time a publication from the country's leading voice for public health focused on firearm violence and its impact on public health.
There were 46,726 firearm-related deaths in the US in 2023, according to data from the US Centers for Disease Control and Prevention. This is just 4% fewer than the three-decade high reached in 2021, when 48,830 people died from firearms.
Trump's pick to follow Murthy as surgeon general, Dr. Janette Nesheiwat, has not yet been scheduled for a confirmation hearing. Nesheiwat is a New York family physician and former Fox News medical contributor who was involved in a gun accident as a child that led to the death of her father, according to The New York Times.
CNN has reached out to Nesheiwat for comment.
Also known as 'the nation's doctor,' the surgeon general is a medical doctor who focuses on educating and advising Americans on how to improve their health by issuing advisories, reports and calls to action to offer the best available scientific information on crucial issues.
The removal of the gun violence advisory comes after the White House Office of Gun Violence Prevention, which was implemented during the Biden administration, apparently ceased operations in January and its website stopped working. The office created the first federal Gun Violence Emergency Response Team, which included the FBI, the Federal Emergency Management Agency and other federal agencies, and coordinated the federal response to mass shootings and community violence.
Dr. Jerome Adams, who was surgeon general during the first Trump administration, said in a news conference Tuesday that firearm injury is a threat to public health.
With more than 48,000 lives lost to firearm-related incidents in previous years, that correlates to about 132 deaths every day, Adams said in a statement, adding that gun violence is the leading cause of death for young people ages 1 to 19.
'If we care about kids and about making America healthy again, we have to address gun violence. More than half of these deaths were due to suicide, highlighting the urgent need for comprehensive public health strategies,' Adams wrote, referencing the phrase often repeated by Trump and HHS Secretary Robert F. Kennedy, that they will 'make America healthy again.'
'I urge policymakers to continue engaging with public health experts, law enforcement, and community leaders to develop evidence-based solutions that prioritize safety and well-being,' Adams wrote. 'In particular, we must focus on suicide prevention, supporting veterans, and expanding access to critical resources like the 988 crisis lifeline to ensure that those in distress receive the help they need. I hope that any changes in public health messaging are made with the best interests of the American people in mind.'
The gun violence prevention organization Giffords, named after its founder, former US Rep. Gabrielle Giffords, has criticized the removal of the surgeon general's gun violence advisory webpage.
'By removing this important public health advisory with lifesaving resources, President Trump has chosen to prioritize gun industry profits over protecting kids and families,' Giffords Executive Director Emma Brown said in a news release Monday. 'Guns have been the number one killer of American children and adolescents since 2020, and non-partisan health care experts have understood gun violence as a public health crisis for years. Under President Trump's first term, gun homicides rose 34%.'
CNN's Emma Tucker contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Long-lasting HIV prevention shot heads toward approval
June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.
Yahoo
an hour ago
- Yahoo
Nearly 100 House Democrats urge RFK Jr. to restore millions in family planning grants
Nearly 100 House Democrats are calling on Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. to restore tens of millions of dollars in federal family planning grants to more than a dozen organizations that have been frozen for more than two months. In a letter to Kennedy sent Friday and seen first by The Hill, 95 lawmakers said the organizations that had their Title X funding frozen on March 31 — including nine Planned Parenthood clinics — are still in the dark about the status of their grants. At the time, the clinics said they received letters from the administration saying the grants were being 'temporarily withheld' due to possible civil right violations and President Trump's executive orders prohibiting the promotion of diversity, equity and inclusion (DEI) and 'taxpayer subsidization of open borders.' More than two months later, the lawmakers said the grantees 'remain without funding and have received no communication from the administration regarding the status of the investigations, the expected timeline, or the future of their funding.' HHS declined to comment, citing ongoing litigation. The agency is being sued over the freeze by the National Family Planning and Reproductive Health Association (NFPRHA) and the American Civil Liberties Union (ACLU). 'Congress has already appropriated these funds, and the administration has a responsibility to distribute them without undue delay or obstruction, ensuring that critical care is not disrupted for millions of people who rely on Title X services,' the group of lawmakers wrote. The letter was led by Reps. Josh Gottheimer (D-N.J.), Judy Chu (D-Calif.), Lizzie Fletcher (D-Texas) and Sharice Davids (D-Kan.) and signed by 91 other Democrats. Title X is the country's only federal program dedicated to providing affordable birth control and other sexual and reproductive health care to low-income Americans and has done so since the 1970s. The lawmakers timed the letter to coincide with the 60th anniversary of the U.S. Supreme Court's ruling in Griswold v. Connecticut, which established a constitutional right to privacy regarding contraception and reproductive decisions. 'However, due to the actions of this administration, reproductive freedom is under threat,' the lawmakers wrote. The first Trump administration prohibited providers from receiving Title X funding if they mentioned abortion or referred patients for abortions. It also required clinics to construct separate facilities for the procedure and other services. More than a dozen grantees, including all Planned Parenthood affiliates nationwide, left the program in protest because of the rule. The Biden administration reversed Trump's Title X rule in 2021. Updated at 3:26 p.m. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Revelation-Backed Omada Health Jumps After $150 Million IPO
(Bloomberg) -- Omada Health Inc. shares ended their debut trading day exactly where they started after the digital health-care company raised $150 million in its initial public offering. Next Stop: Rancho Cucamonga! ICE Moves to DNA-Test Families Targeted for Deportation with New Contract Where Public Transit Systems Are Bouncing Back Around the World US Housing Agency Vulnerable to Fraud After DOGE Cuts, Documents Warn Trump Said He Fired the National Portrait Gallery Director. She's Still There. The stock climbed 21% to close at $23 on Friday in New York — the same price it opened at — higher than its IPO price of $19 per share. The stock had jumped as much as 49% during the the trading session. The San Francisco-based company sold 7.9 million shares at $19 each after offering them at $18 to $20 apiece, according to its filings with the US Securities and Exchange Commission. The trading gives Omada a market value of $1.3 billion based on the number of outstanding shares listed in its filings. The IPO adds to the growing pace of US first-time share sales this year, which have raised around $24.9 billion so far, versus $17.6 billion in the same period last year, according to data compiled by Bloomberg. Shares of health-care upstarts that went public on US exchanges this year are also up by a weighted average of roughly 18%, according to Bloomberg calculations. An IPO last month for digital physical therapy provider Hinge Health Inc. — a competitor to Omada — raised $503 million, and shares have risen about 19% since its debut. Omada's offering closed with orders for more than 15 times the shares available, with allocations going to a highly concentrated group of investors, Bloomberg News has reported. Virtual Care Founded in 2011, Omada provides virtual care in between doctor's visits to help people manage chronic conditions including diabetes and prediabetes, obesity, hypertension and musculoskeletal conditions, according to the filing. Users track metrics including weight, blood pressure and blood glucose values to the company's platform, which includes a mobile app. Unlike other digital health firms, Omada doesn't offer GLP-1 weight loss drugs, the filing shows. Instead it has programs to support people using them, including coaching and nutrition guidance, to manage muscle loss and stop the weight from returning when they cease taking the medication, according to the filing. About 50,000 of Omada's 679,000 members are on GLP-1s, co-founder and Chief Executive Officer Sean Duffy said in an interview with Bloomberg News. It's a relatively new business for the company that has expanded in the past year as part of its partnership with Cigna Group's Express Scripts unit, he said. 'For support, especially in chronic disease, it's very helpful that someone feels they are not just doing this for themselves but for someone else - to have someone rooting for you in your corner is really important for outcomes,' Duffy said. Omada is using AI to automate the virtual care it provides to chronic disease sufferers, though the services are 'human-led,' he said. 'Our members tell us they want a person and I am yet to see anyone that feels accountable to ChatGPT,' Duffy said. Omada has over 2,000 customers including employers and health systems, and more than 679,000 total members enrolled in one or more programs, according to the filing. Largest Shareholder Revelation Partners is Omada's largest shareholder, beneficially owning 10.9% of the company before the offering, according to the filing. USVP has 9.9% of the shares, Andreessen Horowitz has 9.6% and FMR has 9.3%, the filing shows. Omada was valued at more than $1 billion in a 2022 funding round led by Fidelity Management & Research Co., it said in a statement at the time. The company had a net loss of $9.4 million on revenue of close to $55 million in the first three months of 2025, compared with a net loss of nearly $19 million on revenue of $35.1 million in the same period a year earlier, the filing shows. The offering was led by Morgan Stanley, Goldman Sachs Group Inc. and JPMorgan Chase & Co., the filing shows. The company's shares trade on the Nasdaq Global Market under the symbol OMDA. (Updates with closing prices.) Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling YouTube Is Swallowing TV Whole, and It's Coming for the Sitcom Is Elon Musk's Political Capital Spent? Trump Considers Deporting Migrants to Rwanda After the UK Decides Not To ©2025 Bloomberg L.P.
